The Problem: Strength Fades Faster Than Most People Expect
Sarcopenia, the age-related loss of muscle mass and function, is one of the quieter public health problems of aging societies. It rarely announces itself. Jars get harder to open, stairs feel steeper, and a walk that used to be easy becomes a chore. Resistance training remains the gold standard for slowing it, but not everyone can lift hard or often. Frailty, joint pain, chronic illness and plain lack of access all get in the way. That gap is why researchers keep looking for supplements that might help people who can't train much.
A new randomized trial in Archives of Gerontology and Geriatrics tested one candidate: a low-molecular-weight fucoidan extracted from brown seaweed. The results were encouraging for strength and function. They were less so for muscle size.
What Is Oligo-Fucoidan?
Fucoidan is a sulfated polysaccharide found in brown seaweed, and it has attracted attention for a range of biological activities, including potential muscle-supporting effects. The product tested here was an "oligo" form, meaning it has been broken down into smaller fragments of roughly 15 kDa. The assumption behind that is that smaller molecules are easier for the body to handle. The study used a branded product called OliFuco, so the results apply to that formulation and not to seaweed or fucoidan supplements in general.
How the Trial Worked
The 12-week, double-blind, placebo-controlled study randomized 60 community-dwelling adults aged 60 or older into three groups:
- Oligo-Fucoidan alone
- Oligo-Fucoidan plus branched-chain amino acids (BCAAs) and vitamin D
- Placebo
The fucoidan dose was 825 mg twice daily, or 1,650 mg per day. Researchers measured handgrip strength, calf circumference, appendicular lean mass index (a DXA-style measure of limb muscle mass), the five-times sit-to-stand test, the six-minute walk test (6MWT) and isokinetic knee extension strength. A secondary summary of the study from Ergo-Log reports that 46 participants were included in the final analysis. The abstract itself doesn't describe any exercise program, so the findings should be read as supplement effects in everyday-living older adults, not as the result of a new training regimen.
The Headline Result: Grip Strength
Grip strength improved significantly with Oligo-Fucoidan (p < 0.001, effect size r = 0.82). In the fucoidan group, 64.7% of participants beat the minimal clinically important difference, meaning the change was large enough to plausibly matter in daily life. The Ergo-Log write-up puts the gain at roughly 18–23%, though that figure comes from the secondary source and not the abstract.
Grip strength is more than a party trick. It is widely used as a quick marker of overall muscle function in older people, and it is a standard component of sarcopenia screening. A clinically meaningful improvement in 12 weeks is therefore notable.
Walking performance improved too. The 6MWT distance increased significantly (p < 0.001), and 47.1% of participants surpassed the minimal detectable change threshold. A multivariate analysis (MANOVA) across six outcomes showed significant overall group differences, driven mainly by the grip strength gains in the fucoidan group compared with placebo.
The Surprises: No Muscle Gain, and No Bonus From BCAAs + Vitamin D
Two findings complicate the story.
First, muscle mass did not change significantly. The benefit showed up in strength and performance, not in lean tissue. That could mean fucoidan acts on muscle quality, neural function or something else, but this trial can't say which. The one mass-related signal was in the placebo group, whose calf circumference dropped (p = 0.012), while the fucoidan group didn't show that decline.
Second, adding BCAAs and vitamin D did not beat fucoidan alone. Many supplement stacks assume more ingredients mean better results, and this trial doesn't support that assumption. Based on the available summary, the combination arm offered no clear advantage over the simpler single-ingredient arm.
No adverse events were reported during the 12 weeks.
Caveats Worth Taking Seriously
This is a small trial: 60 randomized participants split across three arms. It lasted only 12 weeks, so we don't know whether the gains persist, plateau or fade. The intervention was a single branded, low-molecular-weight product at one dose, and we can't assume other fucoidan supplements behave the same way. The authors themselves call for further research on long-term effects and on optimizing the formulation. Small trials with large effect sizes also deserve replication before anyone treats them as settled.
Practical Takeaways
- Who it might suit: Older adults, especially those with limited ability to do hard resistance training, are the population this research targets.
- Dose studied: 825 mg twice daily (1,650 mg/day) of low-molecular-weight Oligo-Fucoidan for 12 weeks.
- Don't expect bigger muscles: The measurable gains were in strength and walking performance, not muscle mass.
- Skip the add-ons for now: BCAAs plus vitamin D didn't improve on fucoidan alone in this trial.
- Training still wins: The authors reaffirm resistance training as the gold standard. If you can lift, keep lifting. Fucoidan, if it holds up, is a possible adjunct or alternative, not a replacement.
- Talk to a clinician: Anyone with health conditions or on medication should check with a healthcare professional before adding a new supplement.
Bottom Line
This trial suggests that a specific seaweed-derived fucoidan can improve grip strength and walking performance in older adults within three months, with no reported adverse events. That makes it a promising, non-pharmacological idea for people who struggle to train. But it is early, small and product-specific, and it didn't move muscle mass. Treat it as a lead worth following, not a substitute for the barbell, the resistance band or the stairs.
Source: Chang et al. "The effects of Oligo-Fucoidan on muscle function in community-dwelling older adults: A double-blind, randomized, placebo-controlled trial." Archives of Gerontology and Geriatrics (2026). DOI: 10.1016/j.archger.2025.106055. PubMed: 41124892.
